Cleara Biotech

Utrecht, Netherlands · Founded 2018 · Privately Held (backing)

Operator of a biotechnology company intended to eliminate senescent cells to treat age-related pathologies. Cleara Biotech is based in Utrecht, Netherlands and was founded in 2018. It has raised $5 million.

Last price · $/share
—
Implied valuation
—
Total raised
$5.0M
Last round
—

Cleara Biotech key facts

  • Operator of a biotechnology company intended to eliminate senescent cells to treat age-related pathologies.
  • It has raised $5.0M; the latest was Later Stage VC in Feb 2026.
  • Notable investors include FJ Labs, TA Ventures, ROM Utrecht Region, Infinitas Capital, TruVenturo — 11 tracked in total.
  • Status: Privately Held (backing).
Free account
More of Cleara Biotech with a free account
  • ·The complete investor list: 11 names
  • ·Watch Cleara Biotech: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Cleara Biotech funding rounds

No rounds on record

No funding rounds for Cleara Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Cleara Biotech investors

11 investors are on record for Cleara Biotech, including FJ Labs, TA Ventures, ROM Utrecht Region and Infinitas Capital.

About Cleara Biotech

Operator of a biotechnology company intended to eliminate senescent cells to treat age-related pathologies. The company offers therapeutics that can be used to remove senescence-like cancer cells that are a cause of therapy resistance in terminal cancer, enabling physicians to treat their patients effectively.

Sector
Healthcare
HQ
Utrecht, Netherlands
Founded
2018
Employees
9
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation — not yet priced

Cleara Biotech doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.